Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Standard-risk B-cell acute lymphoblastic leukaemia in children, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether blinatumomab allows chemotherapy to be shortened rather than only added to.
Asparaginase hypersensitivity and silent inactivation, and osteonecrosis in older children.
Delivering a two-year outpatient regimen in low- and middle-income countries, where most children with ALL live.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
3-year DFS 96.
3-year OS 85% vs 68%; HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.